Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
William Blair initiated coverage on Applied Therapeutics Inc. (NASDAQ:APLT), a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy.
William Blair对应用治疗公司（Applied Therapeutics Inc.）（纳斯达克：APLT）进行了覆盖，该公司专注于罕见病，如半乳糖血症、SORD缺乏症和糖尿病心肌病的后期开发。
The analyst says, "Applied Therapeutics is an under-the-radar company developing a nice mix of therapeutics targeting rare diseases and some larger indications with potential for several major value inflections over the next 12 months."
分析师表示：“应用治疗公司是一家低调开发罕见疾病和一些具有潜力的更大适应症的公司，未来12个月内可能出现几个主要的价值影响。”
In April, the FDA extended the review period for Applied Therapeutics' marketing application, seeking approval for its potentially first marketed drug govorestat (AT-007) for Classic Galactosemia, by three months.
4月，FDA将针对应用治疗公司的市场申请的审查期限延长了三个月，寻求批准其潜在的第一个市场推出的药物govorestat（At-007）用于经典半乳糖血症。
William Blair anticipates that Applied Therapeutics will launch govorestat in the galactosemia market in 2025, predicting a successful rollout due to the high unmet medical need, absence of other approved therapies, well-identified patient population, and the strong performance of first-in-class rare disease products.
William Blair预测，由于高度不满足的医疗需求、没有其他获批的疗法、被识别的患者人口以及首创罕见疾病产品的强劲表现，应用治疗公司将于2025年在半乳糖血症市场推出govorestat，并预测其成功推出。
The analyst estimates 2030 sales of govorestat to exceed $1 billion with 70% peak penetration in the galactosemia market.
该分析师估计，到2030年，govorestat的销售额将超过10亿美元，在半乳糖血症市场中达到70%的峰值渗透率。
The analyst initiates with an Outperform rating and estimates a fair value for shares of $14.
该分析师给予Outperform评级，并估计股票公允价值为14美元。
Beyond govorestat, Applied Therapeutics is developing AT-001 (caficrestat) for diabetic cardiomyopathy.
除了govorestat外，应用治疗公司还推出了At-001（caficrestat）用于糖尿病心肌病的开发。
Diabetic cardiomyopathy affects about 20% of diabetics and, accordingly, has blockbuster potential.
糖尿病心肌病影响约20％的糖尿病患者，因此具有巨大的潜力。
In February, Applied Therapeutics released interim 12-month results from the ongoing Phase 3 INSPIRE trial of oral govorestat in SORD deficiency patients, in which the primary and several key secondary endpoints were achieved.
2月份，应用治疗公司发布了正在进行的口服govorestat钠盐针对SORD缺乏症患者的III期INSPIRE试验的中期12个月结果，在该试验中，达到了主要和几个关键的次要终点。
The Company expects that its cash and cash equivalents of $146.5 million as of March 31, 2024, will fund the business into 2026.
公司预计，截至2024年3月31日，其现金及现金等价物为14650万美元，将资助业务延续至2026年。
Price Action: APLT stock is up 18.70% at $5.91 at the last check on Wednesday.
最后检查时，APLt股票上涨了18.70％，报5.91美元。
- After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial.
- 报告五例患者死亡后，数据委员会建议MacroGenics停止前列腺癌试验。